Cardiovascular disease in renal transplantation: Management by statins

Transplantation Reviews

Volumn 18, Issue 3, 2004, Pages 122-128

  Fellström, Bengt ^a   Holdaas, Hallvard ^a   Jardine, Alan ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN B; ATORVASTATIN; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; EZETIMIBE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RAPAMYCIN; SIMVASTATIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ARTICLE; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG MECHANISM; DRUG SAFETY; GRAFT DYSFUNCTION; GRAFT FAILURE; GRAFT SURVIVAL; HEART DEATH; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INCIDENCE; INFECTION RISK; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MORBIDITY; MORTALITY; NEPHROTOXICITY; POPULATION RESEARCH; RECIPIENT; RISK FACTOR; RISK REDUCTION; SURVIVAL TIME; TREATMENT PLANNING;

EID: 13944253658     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2004.03.001     Document Type: Article

References (54)

1. Foley R.N. Parfrey P.S. Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease Am J Kidney Dis 32 Suppl 3 1998 S112
2. Kasiske B.L. Guijarro C. Massy Z.A. et al Cardiovascular disease after renal transplantation J Am Soc Nephrol 7 1996 158
3. Johnson D.W. Herzig K. Purdie D. et a.l A comparison of the effects of dialysis and renal transplantation on the survival of older uremic patients Transplantation 69 2000 794
4. Rabbat C.G. Thorpe K.E. Russell J.D. et al. Comparison of mortality risk for dialysis patients and cadaveric first renal transplant recipients in Ontario, Canada J Am Soc Nephrol 11 2000 917
5. Schaubel D. Desmeules M. Mao Y. et al. Survival experience among elderly end-stage renal disease patients. A controlled comparison of transplantation and dialysis Transplantation 60 1995 1389
6. Cosio F.G. Alamir A. Yim S. et al. Patient survival after renal transplantation: I. The impact of dialysis pre-transplant Kidney Int 53 1998 767
7. Lindholm A. Albrechtsen D. Frödin L. et al. Ischemic heart disease-Major cause of death and graft loss after renal transplantation in Scandinavia Transplantation 60 1995 451
8. USRDS Annual Report 1999 Ann Arbor, MI
9. Levey A.S. Beto J.A. Coronado B.E. et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 32 1998 853
10. Jardine A.G. Pretransplant management of end-stage renal disease patients to minimize posttransplant risk Transplantation 70 2000 SS46
11. De Lemos J.A. Hillis L.D. Diagnosis and management of coronary artery disease in patients with end-stage renal disease on hemodialysis J Am Soc Nephrol 7 1996 2044
12. Keane W.F. Derangement of lipid metabolism and its management in renal transplant patients Miner Electrolyte Metab 23 1997 166
13. Kasiske B.L. Hyperlipidemia in patients with chronic renal disease Am J Kidney Dis 32 Suppl 3 1998 S142
14. 3 after renal transplantation Transplantation 46 1988 407
15. Kasiske B.L. Umen A.J. Persistent hyperlipidemia in renal transplant patients Medicine (Baltimore) 66 1987 309
16. Ghanem H. van den Dorpel M.A. Weimar W. et al. Increased low density lipoprotein oxidation in stable kidney transplant recipients Kidney Int 49 1996 488
17. Sutherland W.H. Walker R.J. Ball M.J. et al Oxidation of low density lipoproteins from patients with renal failure Kidney Int 48 1995 227
18. Kasiske B. Risk factors for accelerated atherosclerosis in renal transplant recipients Am J Med 84 1998 985
19. Aakhus S. Dahl K. Wideroe T.E. Cardiovascular morbidity and risk factors in renal transplant patients Nephrol Dial Transplant 14 1999 648
20. Vathsala A. Weinberg R.B. Schoenberg L. et al. Lipid abnormalities in cyclsoporine-prednisone-treated renal transplant recipients Transplantation 48 1989 37
21. Stegall M.D. Wachs M.E. Everson G. et al. Prednisone withdrawal 14 days after liver transplantation with mycophenolate. A prospective trial of cyclosporine and tacrolimus Transplantation 64 1997 1755
22. Hricik D.E. Bartucci M.R. Mayer J.T. et al The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients Transplantation 54 1992 868
23. Lopez-Miranda J. Perez-Jimenez F. Torres A. et al. Effect of cyclosporin on plasma lipoproteins in bone marrow transplantation patients Clin Biochem 25 1992 379
24. Raine A.E. Carter R. Mann J.I. et al. Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients Nephrol Dial Transplant 3 1988 458
25. Ballantyne C.M. Podet E.J. Patsch W.P. et al. Effects of cyclosporine therapy on plasma lipoprotein levels JAMA 262 1989 53
26. Hilbrands L.B. Demacker P.N. Hoitsma A.J. et al. The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients J Am Soc Nephrol 5 1995 2073
27. Schorn T.F. Kliem V. Bojanovski M. et al. Impact of long-term immunosuppression with cyclosporine A on serum lipids in stable renal transplant recipients Transplant Int 4 1991 92
28. van den Dorpel M.A. Ghanem H. Rischen-Vos J. et al. Conversion from cyclosporine A to azathioprine treatment improves LDL oxidation in kidney transplant recipients Kidney Int 51 1997 1608
29. Satterthwaite R. Aswad S. Sunga V. et al. Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine Transplantation 65 1998 446
30. FK506 Kidney Transplant Study Group Jensik S.C. Tacrolimus (FK506) in kidney transplantation: Three-year survival results of the US multicenter, randomized, comparative trial Transplant Proc 30 1998 1216
31. Johnson C. Ahsan N. Gonwa T.A. et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation Transplantation 69 2000 834
32. Pirsch J.D. Miller J. Deierhoi M.H. et al FK506 Kidney Transplant Study Group A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation Transplantation 63 1997 977
33. Groth C.G. Backman L. Morales J.M. et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine Transplantation 67 1999 1036
34. Kahan B.D. Podbielski J. Napoli K.L. et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation Transplantation 66 1998 1040
35. Shapiro R. Jordan M.L. Scantlebury V.P. et al. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone /mycophenolate mofetil in renal transplant recipients Transplantation 67 1999 411
36. Ducloux D. Fournier V. Bresson-Vautrin C. et al. Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity Transplantation 65 1998 1504
37. European Tacrolimus vs Ciclosporin-Microemulsion Renal Transplantation Study Group Margreiter R. A prospective, randomized, multicentre study to compare the efficacy and safety of tacrolimus and ciclosporin-microemulsion in renal transplantation Transplantation 69 Suppl 2000 S112
38. Meier-Kriesche H.U. Baliga R. Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation Transplantation 75 2003 1291
39. Johnson R.W. Sirolimus (Rapamune) in renal transplantation Curr Opin Nephrol Hypertens 11 2002 603
40. Abramowicz D. Manas D. Lao M. et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: A randomized, controlled study Transplantation 74 2002 1725
41. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383
42. West of Scotland Coronary Prevention Study Group Shepherd J. Cobbe S.M. Ford I et-al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med 333 1995 1301
43. Cholesterol and Recurrent Events Trial Investigators Sacks F.M. Pfeffer M.A. Moye L.A. et-al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001
44. Downs J.R. Clearfield M. Weis S. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615
45. Shepherd J. Blauw G.J. Murphy M.B. et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial Lancet 360 2002 1623
46. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT) JAMA 288 2002 2998
47. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349
48. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial Lancet 360 2002 7
49. Wanner C. Krane V. Ruf G. et al. Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis Kidney Int 56 Suppl 71 1999 222
50. Fellstrom B.C. Holdaas H. Jardine A.G. Why do we need a statin trial in hemodialysis patients Kidney Int Suppl 63 84 2003 S204
51. Baigent C. Landry M. Study of Heart and Renal Protection (SHARP) Kidney Int Suppl 63 84 2003 S207
52. Cosio F.G. Pesavento T.E. Pelletier R.P. et al. Patient survival after renal transplantation III: The effects of statins Am J Kidney Dis 40 2002 638
53. Holdaas H. Fellström B. Jardine A.G. et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomized, placebo controlled trial Lancet 14 2003 2024
54. Jardine A. Holdaas H. Fluvastatin in combination with cyclosporin in renal transplant recipients: A review of clinical and safety experience J Clin Pharm Ther 24 1999 397